Calcium Modulatory Properties of 2,6-dibutylbenzylamine (B25) in Rat Isolated Vas Deferens, Cardiac and Smooth Muscle Preparations
Overview
Affiliations
1. In rat isolated vas deferens the new compound 2,6-dibutylbenzylamine (B25) evoked a series of repeating rhythmic contractions. Concentration-response curves constructed for this effect were bell-shaped, indicating a biphasic effect for this compound. By contrast, B25 depressed heart contractility without any visible positive inotropic or chronotropic activity. 2. Experiments with tetrodotoxin, reserpine, capsaicin, alpha-adrenoceptor blocking compounds and other agents permit us to exclude a release of neuromediators or a direct stimulation of post-synaptic receptors to account for the rhythmic effect of B25 in the rat vas deferens. 3. In the same tissue, the increase in 45Ca2+ uptake, the voltage-dependency as well as the dependence of the B25-induced rhythmic activity upon the external calcium concentration indicate a direct activation of voltage-sensitive calcium channels (VSCC). 4. Verapamil paradoxically stimulated the rhythmic effect of B25 in the rat vas deferens. La3+ was inactive while nifedipine was a weak inhibitor. By contrast Ni2+ and Mn2+ ions were good inhibitors (IC50 < 10(-4) M), suggesting that a possible opening of T-type VSCC underlies rhythmic effect of B25. 5. In radioligand binding studies competition experiments with [3H]-nitrendipine indicated that only at high concentrations was B25 able to interact with dihydropyridine-sensitive binding sites of heart and vas deferens smooth muscle. 6. B25 (3-30 microM) counteracted the inhibitory effects of omega-conotoxin GVIA in field-stimulated rat vas deferens.
Caricati-Neto A, Garcia A, Bergantin L Pharmacol Res Perspect. 2015; 3(5):e00181.
PMID: 26516591 PMC: 4618650. DOI: 10.1002/prp2.181.
T-type Ca2+ channels and the urinary and male genital tracts.
Fry C, Jabr R Pflugers Arch. 2014; 466(4):781-9.
PMID: 24463704 DOI: 10.1007/s00424-014-1446-x.
The reduction of food intake induced in mice by benzylamine and its derivatives.
Raimondi L, Banchelli G, Ghelardini C, Pirisino R Inflammopharmacology. 2004; 11(2):189-94.
PMID: 15035821 DOI: 10.1163/156856003765764362.
Pirisino R, Ghelardini C, Banchelli G, Galeotti N, Raimondi L Br J Pharmacol. 2001; 134(4):880-6.
PMID: 11606329 PMC: 1573009. DOI: 10.1038/sj.bjp.0704316.